Search details
1.
Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
BMC Cancer
; 21(1): 146, 2021 Feb 09.
Article
in English
| MEDLINE | ID: mdl-33563241
2.
Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'.
Oncology
; 91(6): 299-301, 2016.
Article
in English
| MEDLINE | ID: mdl-27705967
3.
Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.
Breast Cancer Res Treat
; 153(3): 617-24, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26358708
4.
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Breast Cancer Res Treat
; 146(1): 7-14, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24899084
5.
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 8: e2300513, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38354330
6.
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; : JCO2302078, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38748939
7.
Integrative Oncology and the Clinical Care Network: Challenges and Opportunities.
J Clin Med
; 12(12)2023 Jun 09.
Article
in English
| MEDLINE | ID: mdl-37373639
8.
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300041, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37315265
9.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; 41(33): 5140-5150, 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-37561967
10.
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200609, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37027810
11.
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300385, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-38096472
12.
Dual HER2-targeted approaches in HER2-positive breast cancer.
Breast Cancer Res Treat
; 131(2): 371-83, 2012 Jan.
Article
in English
| MEDLINE | ID: mdl-21956210
13.
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
JCO Precis Oncol
; 6: e2200306, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36315917
14.
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 6: e2200191, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36409971
15.
Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
Pancreas
; 50(1): 29-36, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-33370020
16.
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
J Clin Oncol
; 39(22): 2443-2451, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-33844595
17.
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Target Oncol
; 15(6): 743-750, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33068284
18.
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 4: 757-766, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-35050752
19.
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 3: 1-8, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-35100714
20.
Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
Clin Colorectal Cancer
; 6(9): 641-5, 2007 Sep.
Article
in English
| MEDLINE | ID: mdl-17945036